Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Medical Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Braz J Microbiol. 2022 Dec;53(4):1761-1779. doi: 10.1007/s42770-022-00813-2. Epub 2022 Oct 28.
Meyerozyma guilliermondii has been accepted as a complex composed of Meyerozyma guilliermondii, Meyerozyma carpophila, and Meyerozyma caribbica. M. guilliermondii is a saprophyte detected on human mucosa and skin. It can lead to serious infections in patients with risk factors like chemotherapy, immunodeficiency, gastrointestinal or cardiovascular surgery, and oncology disorders. Most deaths related to M. guilliermondii infections occur in individuals with malignancy. In recent decades, incidence of M. guilliermondii infections is increased. Sensitivity of this microorganism to conventional antifungals (e.g., amphotericin B, fluconazole, micafungin and anidulafungin) was reduced. Prophylactic and empirical uses of these drugs are linked to elevated minimal inhibitory concentrations (MICs) of M. guilliermondii. Drug resistance has concerned many researchers across the world. They are attempting to discover appropriate solution to combat this challenge. This study reviews the most important mechanisms of resistance to antifungals developed by in M. guilliermondii species complex.
毕赤酵母属已被确认为一个由毕赤酵母、卡氏毕赤酵母和加勒比毕赤酵母组成的复合体。毕赤酵母是一种在人体黏膜和皮肤上检测到的腐生菌。它可导致有化疗、免疫缺陷、胃肠或心血管手术以及肿瘤疾病等危险因素的患者发生严重感染。大多数与毕赤酵母属感染相关的死亡发生在恶性肿瘤患者中。近几十年来，毕赤酵母属感染的发生率有所增加。该微生物对常规抗真菌药物（如两性霉素 B、氟康唑、米卡芬净和阿尼芬净）的敏感性降低。这些药物的预防性和经验性使用与毕赤酵母属的最低抑菌浓度（MIC）升高有关。耐药性引起了世界各地许多研究人员的关注。他们正在试图寻找合适的解决方案来应对这一挑战。本研究综述了毕赤酵母属复合体中抗真菌药物耐药性的最重要机制。
